Latest News
News Functions
Additional Functions
25 November 2024
JP Jenkins Ltd
HPC customer engages Sondrel for high end chip design
25 November 2024
JP Jenkins Ltd
Thrive Renewables Plc 2024 Half Year Results for the period ended 30 June 2024
13 November 2024
JP Jenkins Ltd
Eresos Holdings PLC Shares soon to be trading on JP Jenkins
1 November 2024
JP Jenkins Ltd
Sondrel Holdings Ltd Announces CEO transition to Lead Next Phase of Growth
JP Jenkins Ltd
Sondrel Holdings Ltd (SND.JPJ) Announces Appointment of Mark Julio as New CFO
23 October 2024
JP Jenkins Ltd
CAMBRIA AFRICA PLC Shares now trading on JP Jenkins
2 October 2024
JP Jenkins Ltd
Thrive Renewables Plc 2024 Half Year Results for the period ended 30 June 2024
24 September 2024
JP Jenkins Ltd
Bowleven plc shares now trading on JP Jenkins
11 September 2024
JP Jenkins Ltd
BiVictriX Therapeutics plc Shares now trading on JP Jenkins
5 September 2024
JP Jenkins Ltd
350 PPM Limited shares now trading on JP Jenkins
21 August 2024
JP Jenkins Ltd
Sondrel (Holdings) PLC shares now trading on JP Jenkins
20 August 2024
JP Jenkins Ltd
GS Verde acquire Anderson Shaw Corporate Finance
JP Jenkins Ltd
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
14 August 2024
JP Jenkins Ltd
Destiny Pharma initiates research to explore XF drug potential for CF
13 August 2024
JP Jenkins Ltd
Destiny Pharma plc shares now trading on JP Jenkins
JP Jenkins Ltd
Destiny Pharma plc shares now trading on JP Jenkins
8 August 2024
JP Jenkins Ltd
Fulcrum returns to profitability following major strategic turnaround
16 July 2024
JP Jenkins Ltd
e-therapeutics plc, Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors
15 July 2024
JP Jenkins Ltd
Superdry PLC shares now trading on JP Jenkins
3 July 2024
JP Jenkins Ltd
e-therapeutics announces completion of £28.90 million fundraise
28 June 2024
JP Jenkins Ltd
Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers
25 June 2024
JP Jenkins Ltd
Industrial Technical Holdings Ltd. Announces Completion of Consolidated Audits for 2022 and 2023
6 June 2024
JP Jenkins Ltd
Pipeline update and final results for the year ended 31 January 2024
29 May 2024
JP Jenkins Ltd
Thrive Renewables Plc 2023 Annual Results for the period ended 31 December 2023
JP Jenkins Ltd
Sportech Ltd FY 2023 Results pre-announcement
23 May 2024
JP Jenkins Ltd
Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors
17 May 2024
JP Jenkins Ltd
Scirocco Energy plc shares now trading on JP Jenkins
9 May 2024
JP Jenkins Ltd
e-therapeutics plc shares now trading on JP Jenkins
1 May 2024
JP Jenkins Ltd
Redx Pharma Plc Shares now trading on JP Jenkins
29 April 2024
JP Jenkins Ltd
Molecular Energies PLC Shares now trading on JP Jenkins